Aelis Farma关于AEF0117大麻使用紊乱的AEF0117第2B阶段研究显示,在减少大麻消费方面有希望。 Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder shows promise in reducing cannabis consumption.

Aelis Farma已经公布了其AEF0117第2B阶段临床研究的结果,该研究针对的是大麻使用紊乱症患者。 Aelis Farma has released results from its Phase 2B clinical study of AEF0117, targeting individuals with Cannabis Use Disorder (CUD). 这项研究旨在评价AEF0117在减少大麻消费方面的效力。 The study aims to evaluate the efficacy of AEF0117 in reducing cannabis consumption. Indivior PLC还提供了对这些调查结果的深入了解,强调了这些调查结果在解决CUD中的重要性。 Indivior PLC also provided insights into these findings, highlighting their significance in addressing CUD. 预计关于AEF0117的功效和安全的进一步详情将为今后的治疗方案提供参考。 Further details on the efficacy and safety of AEF0117 are anticipated to inform future treatment options.